Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
American Journal of Hematology · 2025
DOI: 10.1002/ajh.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Abiola Bolarinwa und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin Light Chains. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Light chain multiple myeloma (LCMM) is a subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains and accounts for 15%–20% of newly diagnosed MM. A comprehensive comparison of LCMM with MM producing intact immunoglobulin (non‐LCMM) remains limited. In this retrospective study, we described distinct clinical and cytogenetic features and assessed long‐term outcomes in 852 LCMM patients diagnosed between 01/01/2004 and 12/31/2022, compared with non‐LCMM controls matched for age, sex, and year of diagnosis. On univariable analysis, LCMM patients were more likely to present with elevated creatinine (> 2 mg/dL), beta‐2‐microglobulin ≥ 5.5 mg/L, elevated LDH, hypercalcemia, t(11;14), del(13q), and t(6;14). Conversely, IMS‐IMWG high‐risk disease, hyperdiploidy, t(4;14), and serum albumin < 3.5 g/dL were less common. On multivariable analysis, elevated creatinine (OR: 5.1, 95% CI: 1.2–27, p = 0.04), t(11;14) (OR: 2.6, 95% CI: 1.3–5.2, p = 0.006), and del(13q) (OR: 4.1, 95% CI: 2.1–8.2, p < 0.001) were independently associated with LCMM, while IMS‐IMWG high‐risk disease (OR: 0.3, 95% CI: 0.1–0.8, p = 0.02) and hyperdiploidy (OR: 0.3, 95% CI: 0.1–0.7, p = 0.002) were less frequent. Despite these differences, progression‐free survival with frontline treatment (HR: 0.97, 95% CI: 0.84–1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87–1.13, p = 0.94) were similar between LCMM and non‐LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS‐IMWG high‐risk disease, and comparable survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Abiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, Morie A Gertz, Angela Dispenzieri, Eli Muchtar, Wilson Gonsalves, Taxiarchis Kourelis, David Dingli, Rahma Warsame, Nelson Leung, Joselle Cook, Moritz Binder, Yi Hwa, Dragan Jevremovic, S Vincent Rajkumar, Shaji K Kumar
Zitieren
APA
Bolarinwa, A., Zanwar, S., Abdallah, N., Buadi, F. K., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Muchtar, E., Kapoor, P., Gonsalves, W., Kourelis, T., Dingli, D., Warsame, R., Leung, N., Cook, J., Binder, M., Lin, Y., Hwa, Y., Rogers, M. G., …, & Kumar, S. K. (2025). Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma. American Journal of Hematology. https://doi.org/10.1002/ajh.70099
Vancouver
Bolarinwa A, Zanwar S, Abdallah N, Buadi FK, Hayman SR, Gertz MA, et al. Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma. American Journal of Hematology. 2025. doi:10.1002/ajh.70099
BibTeX
@article{Bolarinwa2025,
author = {Bolarinwa, Abiola and Zanwar, Saurabh and Abdallah, Nadine and Buadi, Francis K and Hayman, Suzanne R and Gertz, Morie A and Dispenzieri, Angela and Muchtar, Eli and Kapoor, Prashant and Gonsalves, Wilson and Kourelis, Taxiarchis and Dingli, David and Warsame, Rahma and Leung, Nelson and Cook, Joselle and Binder, Moritz and Lin, Yi and Hwa, Yi and Rogers, Michelle G and Hobbs, Miriam and Fonder, Amie and Jevremovic, Dragan and Rajkumar, S Vincent and Kumar, Shaji K},
title = {Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.70099}
}
EUVIMED